ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2106

Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls

Stephen Oakley1, Samantha Stott1, Kerri Gill1, Chan Virgil1, Lyanne Weston2 and Theo de Malmanche1, 1John Hunter Hospital, New Lambton, Australia, 2Australian Red Cross Blood Service, Alexandria, Australia

Meeting: ACR Convergence 2023

Keywords: Biomechanics, Cardiovascular, Cutaneous, rheumatoid arthritis, Subclinical Cardiovascular Disease

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The risk of developing ACPA+RA, predictors of severity and causes of excess cardiovascular disease (CVD) are incompletely understood. We have observed that RA patients with concurrent benign joint hypermobility have less severe arthritis and lower arterial stiffness. We hypothesise that biomechanical characteristics are similar in different connective tissues within individuals and that Constitutional Stiffness (CS) is a common determinant of RA severity and risk of CVD.

The aimof this study was to evaluate the validity of biomechanical assessments of a single joint (right 5th metacarpophalageal joint R-MCPJ5) as a measure of total body articular stiffness and to compare these assessments with measurements of skin and arterial stiffness in RA and Control.

Methods: Fifty-eight ACPA+RA and 57 controls (47 Healthy Volunteers and 10 Benign Joint Hypermobility) were recruited. R-MCPJ5 stiffness was measured as angular displacement (AD) degrees passive extension in response to a range of torque moments. Stress-strain responses were evaluated. Responses to 0.33Nm torque (AD0.33) were examined in detail. Beighton Scores (BS) used clinically to assess hypermobility were categorised as Low (BS 0), moderate (BS 1-3) and High (BS >3). Skin Stretch (SKST) was measured as percentage increase in distance between 2 dots dorsal right hand upon manual traction (Vernier calipers 0.1 mm resolution). Scores were dichotomised as High Stiffness ≤ 9.7% or Low Stiffness > 9.7%. Arterial stiffness was measured as Carotid-Femoral Pulse Wave Velocity (PWV metres/sec). Scores were dichotomised as High Stiffness ≥ 9.3 m/sec or Low Stiffness < 9.3 m/sec.

Results: Reproducibility (ICC/Kappa): AD0.33 0.94, BS 0.67, SKST 0.27 and PWV 0.99. Stress-Strain responses curves found that R-MCPJ5 assessments correlate with BS. BS correlated with AD0.33 in ACPA+RA (BS0:37, BS1-3:45, BS>3:54, p0.000) and Control (BS0:33, BS1-3:45, BS1-3:53, p0.000). High PWV ( >9.3 m/sec) was associated with lower AD0.33 in ACPA+RA (38 vs 47, p0.011) and Controls (38 vs 43, p0.206). Linear regression found negative correlation with AD0.33 in ACPA+RA (β -0.06, p 0.002) and Controls (β -0.03, p 0.115). PWV correlated negatively with BS in ACPA+RA (BS0:10.5, BS1-3:9.4, BS>3:9.4, p0.207) and Controls (BS0:9.4, BS1-3:9.8, BS>3:7.1, p0.004). SKST correlated with lower AD0.33 significantly in RA <5 years duration (31 vs 44, p0.027) with similar trends for BS in ACPA+RA (BS0:11%, BS1-3:12% BS>3:13%, p0.746) and in Controls for AD0.33 (39 vs 43, p0.2638) and BS (BS0:10%, BS1-3:12%, BS>3:15%, p0.008). Skin stiffness correlated with PWV in Control (OR 1.91, p0.242) and ACPA+RA (Odds Ratio 2.2, p0.157). In RA ≤5 years duration no subjects with High PWV had Low skin stiffness (OR infinite, p0.000). Linear regression PWV correlated negatively with SKST in ACPA+RA of less than 5 years duration (β -0.18, p 0.057) and Controls (β -0.10, p 0.081).

Conclusion: R-MCPJ5 assessments are representative of total body articular biomechanical properties. There is correlation between articular, arterial and skin biomechanical characteristics supporting the construct of CS. CS is a plausible common determinant of articular and arterial disease.

Supporting image 1

Right 5th MCPJ Stress-Strain responses for Rheumatoid Arthritis (dashed lines) and Control (solid lines) subjects. For both groups there is correlation between Right 5th MCPJ Stiffness (Strain responses measured as dorsal angular displacement) and Overall Total Body Articular Stiffness (Beighton Score).

Supporting image 2

Arterial Stiffness (Carotid-Femoral Pulse Wave Velocity) versus Articular Stiffness in RA (red) and Control (black) Groups. Scatterplots with univariate linear regression lines of best fit. Note that Articular stiffness has been expressed as (90 minus Angular Displacement degrees dorsiflexion) so that greater values indicate greater stiffness.

Supporting image 3

Arterial Stiffness (Carotid-Femoral Pulse Wave Velocity) versus Skin Stiffness in RA <5 years duration (red) and Controls (black). Scatterplots with univariate linear regression lines of best fit. Note that skin stretch is expressed as 40 - Percent stretch so that higher values represent greater stiffness.


Disclosures: S. Oakley: AbbVie/Abbott, 5, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Novartis, 6, UCB, 6; S. Stott: None; K. Gill: None; C. Virgil: None; L. Weston: None; T. de Malmanche: None.

To cite this abstract in AMA style:

Oakley S, Stott S, Gill K, Virgil C, Weston L, de Malmanche T. Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-the-construct-of-constitutional-stiffness-cs-in-anti-ccp-antibody-positive-rheumatoid-arthritis-acpara-and-controls/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-construct-of-constitutional-stiffness-cs-in-anti-ccp-antibody-positive-rheumatoid-arthritis-acpara-and-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology